Authors
John Strang, Nora D Volkow, Louisa Degenhardt, Matthew Hickman, Kimberly Johnson, George F Koob, Brandon DL Marshall, Mark Tyndall, Sharon L Walsh
Publication date
2020/1/9
Source
Nature reviews Disease primers
Volume
6
Issue
1
Pages
3
Publisher
Nature Publishing Group UK
Description
Opioid use disorder (OUD) is a chronic relapsing disorder that, whilst initially driven by activation of brain reward neurocircuits, increasingly engages anti-reward neurocircuits that drive adverse emotional states and relapse. However, successful recovery is possible with appropriate treatment, although with a persisting propensity to relapse. The individual and public health burdens of OUD are immense; 26.8 million people were estimated to be living with OUD globally in 2016, with >100,000 opioid overdose deaths annually, including >47,000 in the USA in 2017. Well-conducted trials have demonstrated that long-term opioid agonist therapy with methadone and buprenorphine have great efficacy for OUD treatment and can save lives. New forms of the opioid receptor antagonist naltrexone are also being studied. Some frequently used approaches have less scientifically robust evidence but are nevertheless …
Total citations
202020212022202320242283134167110
Scholar articles
J Strang, ND Volkow, L Degenhardt, M Hickman… - Nature reviews Disease primers, 2020